These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23021089)

  • 1. Re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
    Garg M; Goel A; Prakash J
    Eur Urol; 2013 Jan; 63(1):e6. PubMed ID: 23021089
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2013 Jan; 63(1):e7-8. PubMed ID: 23092542
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C.
    Bryan RT
    Eur Urol; 2012 Nov; 62(5):803-5. PubMed ID: 22728115
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
    Aldemir M; Canda AE; Balbay MD
    Eur Urol; 2010 Aug; 58(2):e23; author reply e24-5. PubMed ID: 20542629
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
    Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R
    Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768
    [No Abstract]   [Full Text] [Related]  

  • 7. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. T. Maeda, E. Kikuchi, K. Matsumoto, A. Miyajima and M. Oya. J Urol 2011; 185: 802-806.
    Serretta V
    J Urol; 2011 Oct; 186(4):1557. PubMed ID: 21855916
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum re "Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study" [Eur Urol 2012;62:797-802].
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2019 Mar; 75(3):e81. PubMed ID: 30409675
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
    Ooi WL; Stockler M; Hayne D
    Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy.
    Raber M; Buchholz N; Vercesi A; Hendawi NA; Inneo V; Di Paola G; Tessa L; Gazzano G; Viglio A; Hasan IM
    Urol Int; 2021; 105(3-4):298-303. PubMed ID: 33333529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Liberati E; Dutto L; Verri C
    Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
    J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
    Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
    Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Kalsi J; Harland SJ; Feneley MR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
    Gözen AS; Umari P; Scheitlin W; Su FE; Akin Y; Rassweiler J
    Arch Ital Urol Androl; 2017 Jun; 89(2):102-105. PubMed ID: 28679178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
    Maffezzini M; Campodonico F; Canepa G; Manuputty EE; Tamagno S; Puntoni M
    Cancer Chemother Pharmacol; 2014 May; 73(5):925-30. PubMed ID: 24585046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.